DK0814778T3 - Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf - Google Patents
Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling derafInfo
- Publication number
- DK0814778T3 DK0814778T3 DK96906751T DK96906751T DK0814778T3 DK 0814778 T3 DK0814778 T3 DK 0814778T3 DK 96906751 T DK96906751 T DK 96906751T DK 96906751 T DK96906751 T DK 96906751T DK 0814778 T3 DK0814778 T3 DK 0814778T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- microparticles
- additives
- block
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19508612 | 1995-03-10 | ||
DE19513659A DE19513659A1 (de) | 1995-03-10 | 1995-04-11 | Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung |
DE1995142837 DE19542837A1 (de) | 1995-11-17 | 1995-11-17 | Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung |
PCT/EP1996/000980 WO1996028143A1 (de) | 1995-03-10 | 1996-03-07 | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0814778T3 true DK0814778T3 (da) | 2001-09-17 |
Family
ID=27214925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96906751T DK0814778T3 (da) | 1995-03-10 | 1996-03-07 | Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf |
Country Status (11)
Country | Link |
---|---|
US (1) | US6346274B1 (da) |
EP (1) | EP0814778B1 (da) |
JP (1) | JP4979843B2 (da) |
AT (1) | ATE201983T1 (da) |
AU (1) | AU5004196A (da) |
CA (1) | CA2214889C (da) |
DK (1) | DK0814778T3 (da) |
ES (1) | ES2159726T3 (da) |
GR (1) | GR3036525T3 (da) |
PT (1) | PT814778E (da) |
WO (1) | WO1996028143A1 (da) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59607089D1 (de) * | 1995-03-10 | 2001-07-19 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
KR100274842B1 (ko) * | 1998-10-01 | 2001-03-02 | 김효근 | 미립구를 이용한 레티노익산의 서방형 약물방출 시스템 |
US6465425B1 (en) * | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
DE10024451A1 (de) * | 2000-05-18 | 2001-11-29 | Asta Medica Ag | Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung |
WO2001089477A2 (en) * | 2000-05-19 | 2001-11-29 | Battelle Memorial Institute | Controlled release of materials from polymer matrices |
FR2809309B1 (fr) * | 2000-05-23 | 2004-06-11 | Mainelab | Microspheres a liberation prolongee pour administration injectable |
KR100376083B1 (ko) * | 2000-07-01 | 2003-03-15 | 주식회사 태평양 | 친수성 또는 염의 형태로 된 약물을 함유하는 서방형생체삽입용 생분해성 고분자 매트릭스 |
FR2811227A1 (fr) * | 2000-07-07 | 2002-01-11 | Philippe Maincent | Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs |
US8257744B2 (en) | 2000-07-07 | 2012-09-04 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
US6967028B2 (en) | 2000-07-31 | 2005-11-22 | Mainelab | Prolonged release microspheres for injectable administration |
WO2002094324A1 (en) * | 2001-05-18 | 2002-11-28 | Institute Of Materials Research & Engineering | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
JP4510384B2 (ja) * | 2001-05-23 | 2010-07-21 | 田辺三菱製薬株式会社 | 骨折治癒促進用組成物 |
JP4510383B2 (ja) | 2001-05-23 | 2010-07-21 | 田辺三菱製薬株式会社 | 軟骨疾患修復治療用組成物 |
AU2002343681B2 (en) | 2001-11-12 | 2006-07-06 | Alkermes Controlled Therapeutics, Inc. | Biocompatible polymer blends and uses thereof |
KR100449893B1 (ko) * | 2001-12-10 | 2004-09-22 | 한국과학기술원 | 폴리에틸렌글리콜을 포함하는 생분해성 고분자를 이용한제자리 임플란트 조성물 |
DE10206517A1 (de) * | 2002-02-16 | 2003-09-04 | Stoess & Co Gelatine | Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung |
US6884432B2 (en) * | 2002-04-25 | 2005-04-26 | Mayo Foundation For Medical Education And Research | Blend, cross-linkable poly(propylene fumarate) for immobilization and controlled drug delivery |
CA2490351C (en) * | 2002-06-25 | 2011-11-01 | Takeda Pharmaceutical Company Limited | Process for producing sustained-release composition |
KR101101261B1 (ko) * | 2002-07-19 | 2012-01-04 | 인스티튜트 오브 머티어리얼스 리서치 & 엔지니어링 | 생체분해성 삼블럭 공중합체, 이의 합성 방법, 및이로부터 제조된 하이드로겔 및 생체물질 |
US20040023322A1 (en) * | 2002-08-01 | 2004-02-05 | Goodheart Clyde R. | Method of producing non-recombinant BMP-2 and use thereof |
WO2004039425A1 (ja) * | 2002-10-29 | 2004-05-13 | Toray Industries, Inc. | 血管塞栓材料 |
ES2347239T3 (es) * | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
ATE492292T2 (de) * | 2003-04-02 | 2011-01-15 | Ares Trading Sa | Flüssige oder gefriergetrocknete pharmazeutische zusammensetzung enthaltend fsh und/oder lh, das nichtionische tensid poloxamer 188 und ein antibakterielles mittel |
US8008255B2 (en) * | 2003-05-30 | 2011-08-30 | Amylin Pharmaceuticals, Inc. | Methods and compositions for enhanced transmucosal delivery of peptides and proteins |
ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
ES2232287B1 (es) * | 2003-07-04 | 2006-11-01 | Advanced In Vitro Cell Technologies, S.L. | Nanoparticulas de derivados polioxietilenados. |
DK1660039T3 (da) * | 2003-07-18 | 2017-01-16 | Oakwood Laboratories L L C | Forebyggelse af reduktion af polymerens molekylvægt, dannelse af urenheder og gelering i polymersammensætninger |
ES2527286T3 (es) * | 2004-04-30 | 2015-01-22 | Abraxis Bioscience, Llc | Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas |
US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
PL2115029T3 (pl) | 2007-02-15 | 2016-01-29 | Tolmar Therapeutics Inc | Poli(laktyd/glikolid) o niskim efekcie nagłego uwalniania i sposoby wytwarzania polimerów |
US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
EP2074988B1 (en) | 2007-12-28 | 2018-03-14 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
WO2010005726A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
JP6363320B2 (ja) | 2008-06-16 | 2018-07-25 | ファイザー・インク | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
NZ590343A (en) | 2008-07-18 | 2012-10-26 | Bristol Myers Squibb Co | Compositions monovalent for cd28 binding and methods of use |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
WO2010075072A2 (en) * | 2008-12-15 | 2010-07-01 | Bind Biosciences | Long circulating nanoparticles for sustained release of therapeutic agents |
CA2753641C (en) * | 2009-02-25 | 2014-09-16 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
TR201906255T4 (tr) | 2009-12-11 | 2019-05-21 | Pfizer | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. |
EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
EP2515946B1 (en) | 2009-12-23 | 2019-05-22 | The Board of Trustees of the University of Illionis | Nanoconjugates and nanoconjugate formulations |
GB201009037D0 (en) | 2010-05-28 | 2010-07-14 | Univ Surrey | Compositions and methods for treating disorders associated with atherosclerotic plaques |
KR101913874B1 (ko) | 2010-11-10 | 2018-10-31 | 인리젠 | 장기 확대를 위한 주사가능 제제 |
TWI641396B (zh) | 2011-09-23 | 2018-11-21 | Bvw控股公司 | 醫療共聚物 |
AU2013315118B2 (en) | 2012-09-17 | 2017-10-05 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
WO2014066699A1 (en) | 2012-10-24 | 2014-05-01 | Tengion, Inc. | Renal cell populations and uses thereof |
WO2014120916A1 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
US20140274873A1 (en) * | 2013-03-14 | 2014-09-18 | Allergan, Inc. | Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process |
EP3116547B1 (en) | 2014-03-14 | 2019-06-05 | Pfizer Inc | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
JP6519659B2 (ja) * | 2015-09-16 | 2019-05-29 | 株式会社島津製作所 | ナノ粒子の製造方法 |
US11345914B2 (en) * | 2017-07-11 | 2022-05-31 | Tokyo University Of Pharmacy And Life Sciences | Composition for delivering nucleic acid and nucleic acid-containing composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5690954A (en) * | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
US5554388A (en) * | 1989-02-25 | 1996-09-10 | Danbiosyst Uk Limited | Systemic drug delivery compositions comprising a polycationi substance |
EP0668073B1 (en) * | 1994-02-21 | 1999-04-14 | Takeda Chemical Industries, Ltd. | Polyester matrix for a pharmaceutical sustained-release preparation |
-
1996
- 1996-03-07 CA CA002214889A patent/CA2214889C/en not_active Expired - Lifetime
- 1996-03-07 JP JP52725196A patent/JP4979843B2/ja not_active Expired - Lifetime
- 1996-03-07 ES ES96906751T patent/ES2159726T3/es not_active Expired - Lifetime
- 1996-03-07 US US08/894,796 patent/US6346274B1/en not_active Expired - Lifetime
- 1996-03-07 DK DK96906751T patent/DK0814778T3/da active
- 1996-03-07 AU AU50041/96A patent/AU5004196A/en not_active Abandoned
- 1996-03-07 PT PT96906751T patent/PT814778E/pt unknown
- 1996-03-07 EP EP96906751A patent/EP0814778B1/de not_active Expired - Lifetime
- 1996-03-07 WO PCT/EP1996/000980 patent/WO1996028143A1/de active IP Right Grant
- 1996-03-07 AT AT96906751T patent/ATE201983T1/de active
-
2001
- 2001-09-05 GR GR20010401385T patent/GR3036525T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
GR3036525T3 (en) | 2001-12-31 |
PT814778E (pt) | 2001-11-30 |
AU5004196A (en) | 1996-10-02 |
EP0814778A1 (de) | 1998-01-07 |
US6346274B1 (en) | 2002-02-12 |
JPH11501642A (ja) | 1999-02-09 |
CA2214889C (en) | 2005-05-24 |
ES2159726T3 (es) | 2001-10-16 |
JP4979843B2 (ja) | 2012-07-18 |
WO1996028143A1 (de) | 1996-09-19 |
EP0814778B1 (de) | 2001-06-13 |
CA2214889A1 (en) | 1996-09-19 |
ATE201983T1 (de) | 2001-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0814778T3 (da) | Polypeptidholdige farmaceutiske administrationsformer i form af mikropartikler og fremgangsmåde til fremstilling deraf | |
DK0785776T3 (da) | Fremstilling af proteinmikrosfærer, film og coatings | |
BR9915198A (pt) | Composto dds e método para medição do mesmo | |
DK1137400T3 (da) | Præparater indeholdende et peptid og polymælkesyre-glycolsyre egnet til fremstilling af subkutane implantater med en forlænget frigivelsesperiode | |
DE69637480D1 (de) | Bioaktive il-12 fusionsproteine | |
ATE335011T1 (de) | Verfahren zur vernetzung von hyaluronsäure mit polymeren | |
ATE344275T1 (de) | Verfahren zur herstellung eines agglomerats von n-(n-(3,3-dimethylbutyl)-l- alpha aspartyl)-l- phenylalanine-1-methylester | |
ATE350015T1 (de) | Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung | |
CY1106620T1 (el) | Μεθοδος για την παραγωγη τριπεπτιδιων | |
DK0513072T3 (da) | Forbedret cyclodextrinbaseret erythropoietinformulering | |
DE68927669D1 (de) | Verfahren zur herstellung von in lösungsmitteln verdünnbaren mikroträgern | |
ATE252375T1 (de) | Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung | |
IT8920169A0 (it) | Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. | |
HUP0302050A2 (hu) | Peptidek beadására alkalmas gyógyszerforma, eljárás az elżállítására és alkalmazása | |
ATE127846T1 (de) | Herstellung von hv/hb copolymer. | |
DE69900756T2 (de) | Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung | |
DK1014948T3 (da) | Lyofiliseret farmaceutisk præparat som er beregnet til at efterligne et lægemiddel på basis af proteiner eller polypeptider | |
Li et al. | Engineering hydrolytic degradation behavior of poly (lactic-co-glycolic acid) through precise control of monomer sequence | |
ES2153648T3 (es) | Polimeros con estado fisico y bioerosionabilidad controlados. | |
DK1165052T3 (da) | Mikroporöst, ekspanderet, isotropt eller struktur med hurtig oplösning til farmaceutisk, veterinær, diætetisk, levnedsmiddelmæssig eller kosmetisk anvendelse og fremgangsmåde til opnåelse deraf | |
JPH01160496A (ja) | 融合タンパク質の選択的分解方法 | |
DE69713477T2 (de) | Verfahren zur Herstellung von Polyhydroxycarbonsäure | |
Belikov et al. | Plasteins. Their preparation, properties, and use in nutrition | |
NO980103L (no) | Stabilisert farmasöytisk preparat som omfatter et veksthormon og et peptid omfattende minst én basisk aminosyrerest og minst én sur aminosyrerest | |
DE60108889D1 (de) | Verfahren zur herstellung von 5-hydroxymethyl-2-oxazolidinon und neues zwischenprodukt |